Nonopioid drug combinations for cancer pain: protocol for a systematic review.
Analgesic therapy
Cancer pain
Clinical trials
Drug combinations
Opioid therapy
Systematic review
Journal
Pain reports
ISSN: 2471-2531
Titre abrégé: Pain Rep
Pays: United States
ID NLM: 101683899
Informations de publication
Date de publication:
Historique:
received:
02
06
2020
revised:
04
08
2020
accepted:
24
08
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Pain related to cancer, and its treatment, is common, may severely impair quality of life, and imposes a burden on patients, their families and caregivers, and society. Cancer-related pain is often challenging to manage, with limitations of analgesic drugs including incomplete efficacy and dose-related adverse effects. Given problems with, and limitations of, opioid use for cancer-related pain, the identification of nonopioid treatment strategies that could improve cancer pain care is an attractive concept. The hypothesis that combinations of mechanistically distinct analgesic drugs could provide superior analgesia and/or fewer adverse effects has been tested in several pain conditions, including in cancer-related pain. Here, we propose to review trials of nonopioid analgesic combinations for cancer-related pain. Using a predefined literature search strategy, trials-comparing the combination of 2 or more nonopioid analgesics with at least one of the combination's individual components-will be searched on the PubMed and EMBASE databases from their inception until the date the searches are run. Outcomes will include pain intensity or relief, adverse effects, and concomitant opioid consumption. This review is expected to synthesize available evidence describing the efficacy and safety of nonopioid analgesic combinations for cancer-related pain. Furthermore, a review of this literature will serve to identify future research goals that would advance our knowledge in this area.
Identifiants
pubmed: 33134752
doi: 10.1097/PR9.0000000000000856
pii: PAINREPORTS-D-20-0054
pmc: PMC7593013
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e856Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.
Déclaration de conflit d'intérêts
A. Caraceni reports personal fees from Kyowa Kirin; Gruenenthal GmbH; Pfizer; Almiral; Helsin Healthcare; Molteni & C Soc Esercizio Spa; Shionogi; Italfarmaco; Sandoz International GmbH; Institute de Recherche “Pierre Fabre”, grants from Molteni & C Soc Esercizio Spa; Prokstrakan; Gruenenthal GmbH; Amgen; and Ipsen, outside the submitted work. D.E. Moulin reports personal fees from Bristol Myers Squibb, personal fees from Spectrum Therapeutics, outside the submitted work. I. Gilron reports personal fees from Adynxx, personal fees from Biogen, personal fees from Eupraxia, personal fees from Novaremed, and personal fees from Teva, outside the submitted work. The remaining authors have no conflicts of interest to declare.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Références
J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9
pubmed: 27112310
Pain. 2017 Jun;158(6):1118-1125
pubmed: 28267066
Lancet Oncol. 2012 Feb;13(2):e58-68
pubmed: 22300860
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Annu Rev Public Health. 2015 Mar 18;36:559-74
pubmed: 25581144
Indian J Palliat Care. 2020 Jan-Mar;26(1):13-18
pubmed: 32132777
Expert Opin Pharmacother. 2003 Oct;4(10):1697-708
pubmed: 14521480
Curr Oncol. 2019 Jun;26(3):e410-e413
pubmed: 31285686
Pain. 2015 May;156(5):958-66
pubmed: 25719617
JAMA. 2018 Sep 4;320(9):871-872
pubmed: 30098170
Cancer. 2018 Jun 15;124(12):2491-2497
pubmed: 29499072
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008943
pubmed: 22786518
J Pain Symptom Manage. 2006 Nov;32(5):444-52
pubmed: 17085270
Pain. 2001 May;92(1-2):147-57
pubmed: 11323136
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Pain. 2015 Aug;156(8):1440-8
pubmed: 25749306
Cochrane Database Syst Rev. 2017 Jul 06;7:CD012592
pubmed: 28683172
N Engl J Med. 2005 Mar 31;352(13):1324-34
pubmed: 15800228
J Clin Oncol. 2004 Jul 15;22(14):2909-17
pubmed: 15254060
Palliat Med. 2018 Jan;32(1):276-286
pubmed: 28604172
Ann Intern Med. 1987 Aug;107(2):224-33
pubmed: 3300460
Pain. 2016 Jul;157(7):1532-40
pubmed: 26982602
Pharmacol Rev. 1989 Jun;41(2):93-141
pubmed: 2692037
Lancet. 1991 Feb 23;337(8739):465-8
pubmed: 1704089
Lancet Neurol. 2013 Nov;12(11):1084-95
pubmed: 24074723
Am Soc Clin Oncol Educ Book. 2019 Jan;39:24-35
pubmed: 31099619
J Natl Compr Canc Netw. 2018 Jun;16(6):719-726
pubmed: 29891523
J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
pubmed: 11504778
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD008886
pubmed: 21975788
Clin J Pain. 2016 Aug;32(8):719-25
pubmed: 26491936
Pain. 2019 Jan;160(1):38-44
pubmed: 30586069
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Am J Hosp Palliat Care. 2007 Oct-Nov;24(5):430-9
pubmed: 17582029
Cochrane Database Syst Rev. 2018 Feb 19;2:CD010585
pubmed: 29457627
JAMA. 1995 Dec 20;274(23):1870-3
pubmed: 7500538
J Natl Compr Canc Netw. 2019 Aug 1;17(8):977-1007
pubmed: 31390582
Lancet. 2009 Oct 10;374(9697):1252-61
pubmed: 19796802